Univalor

Liphorus Pharmaceuticals Inc. is a Montreal-based company founded in 2014 that focuses on the development of innovative pharmaceuticals. The company specializes in creating small molecules and therapeutic antibodies aimed at targeting PCSK9, a key protein involved in regulating cholesterol levels. Liphorus's products are designed for the treatment of hypercholesterolemia, helping patients to effectively lower LDL, or "bad" cholesterol levels, through oral administration. By leveraging advanced biotechnological techniques, Liphorus Pharmaceuticals aims to provide enhanced solutions for managing cholesterol-related health issues.